KYNB Earnings Date & History
Kyntra Bio Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:18 PM ET
Kyntra Bio Inc
Biotechnology
- Next earnings date
- Monday, November 9, 2026
- Reporting session
- After Close
- EPS estimate
- $-3.40
- Revenue estimate
- $2.0M
KYNB earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-3.25 | $-4.68 | -44.1% | $-1.5M |
| Monday, May 11, 2026 | Q1 2026 | $-3.42 | $-3.76 | -9.9% | $3.7M |
| Monday, March 16, 2026 | Q4 2025 | $-3.96 | $-3.61 | +8.9% | $1.3M |
| Monday, November 10, 2025 | Q3 2025 | $-4.09 | $-3.25 | +20.4% | $1.1M |
| Monday, August 11, 2025 | Q2 2025 | $-2.35 | $-1.88 | +20.0% | $1.3M |
What the market is watching in KYNB's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next KYNB earnings date?
- Kyntra Bio Inc is scheduled to report on Monday, November 9, 2026 (After Close). Dates can change until the company confirms them.
- Does KYNB report before or after the market?
- The next report is scheduled after close.
- What EPS is expected for KYNB?
- Consensus EPS for the upcoming quarter is $-3.40, on revenue of $2.0M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
KYNB earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.